Update (June 25, 2026): ICADA 2015 Updated Guidelines for Treatment of Canine Atopic Dermatitis

Bottom line.

• The 2015 ICADA guidelines — the first 5-year minor update of the international consensus document for treatment of atopic dermatitis (AD) in dogs — recommend that acute flares be managed with bathing, plus topical and/or oral glucocorticoids or oclacitinib; chronic AD should begin with identification and avoidance of flare factors and adequate skin and coat hygiene.¹
• The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and (where available) injectable recombinant interferons; allergen-specific immunotherapy and proactive intermittent topical glucocorticoid application are the only interventions likely to prevent or delay recurrence of flares.¹
• Treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages; a multifaceted, combined-intervention approach is recommended for proven or likely optimal benefit.¹
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Guideline facts

• Issuing body: International Committee on Allergic Diseases of Animals (ICADA; formerly International Task Force on Canine Atopic Dermatitis).¹
• Publication: Olivry T, DeBoer DJ, Favrot C, et al. BMC Vet Res 2015;11:210. DOI 10.1186/s12917-015-0514-6.¹
• Update type: First 5-year minor update of the 2010 consensus guidelines; evidence rated using the Strength of Recommendation Taxonomy (SORT).¹
• Scope: Pharmacotherapy and non-pharmacological management of acute and chronic canine AD; prevention of flare recurrence; allergen-specific immunotherapy.¹

Navigating the ICADA framework in practice?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Background and development

In 2010, the International Task Force on Canine Atopic Dermatitis published the first consensus guidelines for treatment of AD in dogs. The 2015 ICADA document represents the first 5-year minor update of this foundational document, incorporating evidence from new randomized controlled trials and systematic reviews published between 2010 and 2014.¹ Evidence was graded using the SORT taxonomy, providing clinicians with explicit strength-of-recommendation labeling for each intervention.

Acute flare management

For the management of acute flares, the guidelines recommend: (1) searching for and eliminating the cause of the flare; (2) bathing with mild shampoos; and (3) controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib.¹ Topical glucocorticoids are recommended for localized lesions, while oral agents are appropriate for more generalized presentations. Oclacitinib's rapid onset (1–2 days) makes it particularly suitable for acute pruritus control.

Chronic canine AD — first-line steps

For chronic canine AD, the guidelines state that the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake.¹ These environmental and skin-care measures are foundational and should be implemented regardless of pharmacological choices.

Pharmacotherapy for chronic AD

The guidelines identify the medications currently most effective in reducing chronic pruritus and skin lesions as: topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons.¹ No single agent is universally preferred; treatment plans are likely to vary between dogs and, for the same dog, between different stages of disease. The guidelines emphasize that interventions should be combined for a proven (or likely) optimal benefit.

Prevention of flare recurrence

Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are identified as the only interventions likely to prevent or delay the recurrence of flares of AD.¹ This positions allergen immunotherapy as the only disease-modifying strategy currently supported by evidence, while proactive topical glucocorticoid therapy provides a practical option for dogs with predictable flare patterns.

How this fits clinical practice

The ICADA framework provides a structured, evidence-graded approach to the heterogeneous presentation of canine AD. Clinically, the most useful aspect of the guidelines is the explicit stage-based approach: distinct recommendations for acute versus chronic disease avoid the common error of treating all presentations identically. The emphasis on identifying and avoiding flare factors (including food allergens, environmental allergens, and secondary infections with Staphylococcus pseudintermedius or Malassezia) before escalating pharmacotherapy reflects best evidence. The 2015 update incorporated oclacitinib as a guideline-endorsed agent; subsequent updates will need to incorporate lokivetmab (approved after 2015) and more recent dupilumab-analogue biologics. Do not infer specific doses from this summary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, Prélaud P; International Committee on Allergic Diseases of Animals. 2015. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 11:210. https://pubmed.ncbi.nlm.nih.gov/26276051/
2. Olivry T, DeBoer DJ, Favrot C, et al.; International Task Force on Canine Atopic Dermatitis. 2010. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 21(3):233-248. https://pubmed.ncbi.nlm.nih.gov/20456716/

Changelog

• 2026-06-25: First published.